# A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

> **NCT03251924** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 80 (actual)

## Conditions studied

- Cancer
- Tumors
- Neoplasm
- Malignancy

## Interventions

- **DRUG:** BMS-986226
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Tetanus Vaccine

## Key facts

- **NCT ID:** NCT03251924
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-01
- **Primary completion:** 2021-12-20
- **Final completion:** 2021-12-20
- **Target enrollment:** 80 (ACTUAL)
- **Why stopped:** Study CA021-002 was terminated because the Sponsor discontinued further development of BMS-986226 due to a change in business objectives. The decision for the study closure was not related to any safety concerns associated with BMS-986226.
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03251924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03251924, "A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03251924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*